RxDoctor Payments Data

Aung Tun, MD

Hematology · Westwood, KSNPI 1033508304

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,467 of the $16,585 with a category attached, or 81.2%. ADC Therapeutics America, Inc. accounts for 66.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $10,979 and has fallen 60.8% since, to $4,307 in 2025.

$16,585in general payments, 2019–2025

Across 57 payments — averaging $290.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ADC Therapeutics America, Inc.$11K
  • Acrotech Biopharma Inc.$4K
  • Adaptive Biotechnologies Corporation$338
  • Novartis$187
  • Genentech USA, Inc.$174
  • AstraZeneca$164
  • plus $754 from 14 others
$2,575,087in research payments, 2019–2025

Across 246 payments — averaging $10,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$2.2M
  • Pfizer$343K
  • F. Hoffmann-la Roche AG$8K

What the payments were for

  • Consulting fees$13,46781%
  • Travel & lodging$7595%
  • Food & beverage$2,35914%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$88,345
Medicare patients
319
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib35$643,579
BrukinsaZanubrutinib28$388,200
CalquenceAcalabrutinib Maleate19$278,843
Bexarotene15$16,253
Acyclovir48$1,274
Potassium Chloride14$374
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim77$312
Duloxetine Hcl13$287
Pantoprazole Sodium21$283
Gabapentin23$249
Fluconazole14$164
Levofloxacin14$127
Prednisone30$100
Allopurinol11$96
Mirtazapine13$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$164$278,84319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Kansason file to place this against a meaningful peer group, so we don't.

Other hematology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →